We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AVRA Medical Robotics Inc (PK) | USOTC:AVMR | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.17 | 0.00 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
As used in this Current Report on Form 8-K (this “Report”), the terms “SSII,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. f/k/a Avra Medical Robotics, Inc. and its subsidiaries.
Item 7.01 Regulation FD Disclosure.
On August 8, 2023, SSII issued a press release announcing that on August 8, 2023, it will be presenting at the MoneyShow’s Investment Masters Symposium being held from August 8-10, 2023 at the Paris Las Vegas Resort in Las Vegas, Nevada.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, and a pioneer in robotic cardiothoracic surgery, will deliver a keynote presentation with Dr. Frederic Moll, the founder of Intuitive Surgical, the global leader in minimally invasive robotic surgery.
The joint presentation will be titled: “SSII Is Shaping a New Era in Robotic Surgery,” and will be followed by a workshop session for conference attendees.
Copies of the press release and the presentation are attached as Exhibits 99.1 and 99.2 to this Report, respectively.
The foregoing information, including the press release and presentation attached as Exhibits 99.1 and 99.2 to this Report, respectively, is being furnished pursuant to Item 7.01 of this Current Report and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended or incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
99.1* |
||
99.2* | Presentation, dated August 8, 2023 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* | Furnished but not filed. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 8, 2023 | SS INNOVATIONS INTERNATIONAL, INC. | |
By: | /s/ Sudhir Srivastava | |
Sudhir Srivastava, M.D. Chairman and Chief Executive Officer |
2
Exhibit 99.1
SS Innovations and Dr. Frederic Moll to Deliver Keynote Presentation at the MoneyShow Investment Masters Symposium, Las Vegas
Dr. Moll, known as the ‘father of robotic surgery’, is the founder of Intuitive Surgical and creator of the da Vinci surgical system.
Fort Lauderdale, FL., August 8, 2023 - News Direct - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that it will present at the MoneyShow Investment Masters Symposium Las Vegas, held from August 8-10, 2023 at the Paris Las Vegas resort.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, and a pioneer in robotic cardiothoracic surgery, will deliver a keynote presentation with Dr. Frederic Moll, the founder of Intuitive Surgical, the global leader in minimally invasive robotic surgery.
The joint presentation will be titled: “SSII Is Shaping a New Era in Robotic Surgery,” and will be followed by a workshop session for conference attendees.
Dr. Srivastava said, “We are very pleased to have the opportunity to showcase our flagship surgical robotic system, the SSi Mantra, at MoneyShow’s prestigious Investment Masters Symposium. I am delighted to join with Dr. Moll to highlight how SS Innovations is shaping the future of robotic surgery with our cost-effective, state of the art, surgical device.
“This an exciting time for SS Innovations, as we prepare to pursue FDA and CE regulatory approvals for our SSi Mantra surgical robotic device.”
The SSi Mantra is the first surgical system to be made in India, and one of the only systems in the world to be distinctly cost-effective with broad-spectrum surgical applications, including cardiovascular, thoracic, head and neck, gynecology, urology and general surgery. The device has been granted regulatory approval in India and is clinically validated in more than 40 different types of surgical procedures.
SS Innovations anticipates receiving regulatory approvals for the SSi Mantra in the United States and Europe in 2024 and 2025.
About SS Innovations International, Inc.
SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at ssinnovations.com or LinkedIn for updates.
About SSi Mantra
Supporting advanced, affordable, and accessible robotic surgery, the SSi Mantra Surgical Robotic System provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more. With its modular, 3D vision open-console design and superior ergonomics, the system engages machine learning models to improve safety and efficiency during procedures. The SSi Mantra system has received Indian Medical Device regulatory approval (CDSCO) and is clinically validated in India in more than 40 different surgical procedures. The company expects to seek regulatory approvals from the US Food and Drug Administration (FDA) and CE Mark in Europe in 2023 and 2024.
Forward-Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations International’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
For more information:
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341
Exhibit 99.2
Cover |
Aug. 08, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Aug. 08, 2023 |
Entity File Number | 333-216054 |
Entity Registrant Name | SS INNOVATIONS INTERNATIONAL, INC. |
Entity Central Index Key | 0001676163 |
Entity Tax Identification Number | 47-3478854 |
Entity Incorporation, State or Country Code | FL |
Entity Address, Address Line One | 1600 SE 15th Street |
Entity Address, Address Line Two | #512 |
Entity Address, City or Town | Fort Lauderdale |
Entity Address, State or Province | FL |
Entity Address, Postal Zip Code | 33316 |
City Area Code | 954 |
Local Phone Number | 478-1410 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
1 Year AVRA Medical Robotics (PK) Chart |
1 Month AVRA Medical Robotics (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions